Segulah IV’s portfolio company CCS Healthcare acquires pharma­ceutical skin care product Propyless

11 November, 2013

On November 8, 2013, CCS Healthcare has entered into an agreement with Merck Sharp & Dohme (Sweden) AB to acquire the pharmaceutical skin care product and trade­mark Propyless.

Propyless is a lotion, based on active substance propylene glycol, used for dry skin, atopic dermatitis and psoriasis. Introduced in the late 1980s it is a well known registered trademark in the Swedish market.

“Propyless is a leading product in its niche on the Swedish market and fits well with our targeted growth strategy. It complements well our current pharmaceutical and skin care offering” says Jonas Nilsson, CEO of CCS Healthcare.

With sales of approx. MSEK 500 and headquartered in Borlänge, Sweden, CCS Health­care is a leading Nordic manufacturer and distributor of personal care and healthcare products, focused on skin care, pharmaceuticals and dental products. CCS Healthcare is market leader in disinfection in Sweden and Norway with its Dax and Antibac brands.

For further information, please visit www.ccshc.comwww.segulah.se or contact:

Christian Sievert, Partner, Segulah Advisor AB
Tel: +46 8 402 87 00, Cell: +46 70 866 96 94
E-mail: sievert@segulah.se

Christian Tegenmark, Junior Partner, Segulah Advisor AB
Tel: +46 8 402 87 00, Cell: +46 70 767 12 92
E-mail: tegenmark@segulah.se


  • Ladda ner PDF
  • News Archive

    2018

    2017

    2016

    2015

    2014

    2013

    Earlier